Ranbaxy Laboratories Limited News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Ranbaxy Laboratories Limited from all sources in a single place.

Load latest

20 Aug 2016

4 Ranbaxy execs quit as Sun Pharma wraps up rejig

Economic Times

MUMBAI: Sun Pharma seems to have completed the last leg of its massive manpower restructuring post its $3.2-billion acquisition of Ranbaxy Laboratories, with four senior executives exiting the company over the last two months. With the latest round, the entire top rung of erstwhile Ranbaxy vice-presidents and above has quit over a span of nearly two years. The restructuring is said to have impacted as many as 3,000 people across several levels and functions. In this round, Alexander Gebauer, president-R&D Subodh Deshmukh, senior VP-R&D (formulations); Vijayaraghavan B, VP (intellectual property and patents); and Poonam Bharti, director-HR, have left the company. When contacted, a Sun Pharma spokesperson declined to comment. Ranbaxy's total headcount was 14,000, with a top-heavy structure at the time of the acquisition, which posed a big challenge to the integration process. No data is available on the number of executives who have resigned or were asked to leave. Also, the issue of salary parity emerged as the average remuneration of Ranbaxy executives ranked senior manager and above was 15-40% higher than the corresponding positions at Sun Pharma. Over a period, Sun Pharma executed three to four rounds of manpower rationalization, starting from the topmost level of president, percolating to vice-presidents and directors. In March last year, Sun Pharma MD Dilip Shanghvi had told TOI the company will "use and nurture the talent" of Ranbaxy, and "is not considering any job cuts". Gebauer, formerly the R&D chief of German specialty research firm Merz Pharma, had joined Ranbaxy in July 2014, while Vijayaraghavan was an old...

Ranbaxy Laboratories Limited

18 Aug 2016

Law firms open doors to whistleblowers as manufacturer violations grow

Economic Times

Industry insiders say interest of whistleblowing firms in India has grown after the Ranbaxy scandal and these are nudging employees of outsourcing cos to report frauds.

Law firms open doors to whistleblowers as manufacturer violations grow

Economic Times | 18 Aug 2016

Ranbaxy Laboratories Limited

12 Aug 2016

Hold Daiichi for contempt of court responsible for leak: RH Holdings

Economic Times

The company's statement came in the wake of a news report that said Ranbaxy's promoters duped Japanese drugmaker Diiachi Sankyo by withholding an internal report.

Ranbaxy Laboratories Limited

11 Aug 2016

Ranbaxy-Daiichi affair: How & why the deal went south

Business Standard

As far back as 2004, Ranbaxy was well aware of the possible repercussions of its alleged improper regulatory filings

Ranbaxy Laboratories Limited

24 Jun 2016

Ranbaxy whistle blower Dinesh Thakur suggests strict prosecution laws to fix drug industry

Economic Times

Dinesh Thakur says the country needs strict criminal prosecution against suppliers of substandard drugs, a nationwide product recall system.

Ranbaxy Laboratories Limited

31 May 2016

Six business lessons from the DaiichiRanbaxy deal fiasco

livemint

In 2008, Daiichi had bought the Singh brothers' 34.82% stake for $2.4 billion. The total deal value was $4.6 billion. Problems emerged soon after the acquisition, when Ranbaxy's plants came under scrutiny by the US FDA

FDA inspections at Ranbaxy plants expected in FY17, says Dilip Shanghvi

livemint | 31 May 2016

Ranbaxy Laboratories Limited

13 May 2016

Not aware of adverse findings about mfg units of Ranbaxy: Sun

Economic Times

MUMBAI: Sun Pharmaceutical Industries said it isn't aware of any adverse findings related to the manufacturing plants of Ranbaxy Laboratories which it acquired in 2014 that are said to be part of an affidavit filed in the Supreme Court by the regulator. "Based on our understanding of the matter, there is no truth to the assertions you are making," a Sun spokesperson said in an email to ET. The affidavit was submitted by the Drug Controller General of India (DCGI) following a public interest litigation (PIL) filed by activist-lawyer ML Sharma. A media report had said this contained the references to the Ranbaxy plants based on observations made in June-July 2013. ET hasn't seen the document. Sharma filed the PIL in February seeking closure of Ranbaxy's three manufacturing plants in India. There was no response to an email sent to the regulator's office on Wednesday. Phone calls to GN Singh, the drug controller general of India, went unanswered. Ranbaxy's troubled history dates to 2008, when the US Food and Drug Administration stopped the company from selling more than two dozen drugs due to manufacturing violations. A year after that, the regulator said the company falsified data. It's most serious setback...

Ranbaxy Laboratories Limited

07 May 2016

Former Ranbaxy promoters fined Rs 3,500 crore, not Rs 2,562 crore: Daiichi

Zee Business

Just a day after new about former Ranbaxy promoters Malvinder Singh and Shivinder Mohan Singh getting fined in tune of Rs 2,562 crore by an arbitration court in Singapore as a punishment for hiding facts from the buyers Daiichi Sankyo, the Japanese company has claimed that the fine amount is about Rs 3,500 crore.

Ranbaxy Laboratories Limited

05 May 2016, 03:16PM

Former Ranbaxy promoters Malvinder and Shivinder Mohan Singh fined Rs 2,600 cr for hiding facts from Daiichi

Economic Times

US subsidiary of Ranbaxy pleaded guilty to 7 felonies relating to the manufacture and distribution of certain adulterated drugs made at units in India.

Former Ranbaxy owners will have to pay Rs1,000 crore more, says Daiichi

livemint | 06 May 2016 9 more

Ranbaxy Laboratories Limited

08 Mar 2016

Indian scientists develop breakthrough dengue drug

The Financial Express

The project was jointly undertaken by DBT, ICGEB and Ranbaxy Research Laboratory and employed Ayurveda in devising the drug In a breakthrough move that can help in the fight against dengue, a herbal medicine against it is claimed to have been developed by scientists in India, which accounts for 50 per cent of the global []

Is Ranbaxy Laboratories Limited worth buying?

5 Votes:

Buy 40.0%

Hold 60.0%